Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
Takeshi YamashitaYukihiro KoretsuneMayumi IshikawaKazuhito ShiosakaiSeiji KogurePublished in: Journal of arrhythmia (2018)
The majority (90.8%) of patients continued medication and no significant safety concerns related to edoxaban were reported during the first 3 months of treatment. Clearer safety and efficacy profiles of edoxaban await data analyses after the 2-year follow-up period.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- direct oral anticoagulants
- oral anticoagulants
- ejection fraction
- left atrial appendage
- newly diagnosed
- healthcare
- chronic kidney disease
- public health
- heart failure
- left atrial
- peritoneal dialysis
- electronic health record
- machine learning
- big data
- deep learning
- mitral valve
- coronary artery disease